Business
Preliminary Results for year ended 30 April 2018
Preliminary Results for year ended 30 April 2018.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 6487V Angle PLC 25 July 2018 \n\n\n\n\nFor Immediate Release \n\n\n25 July 2018\n\n\n\n \nANGLE plc\n(\"ANGLE\" or \"the Company\")\n \nPreliminary Results for the year ended 30 April 2018\n \nSTRENGTHENING A LEADING POSITION IN THE LIQUID BIOPSY MARKET\n \n OVARIAN CANCER CLINICAL STUDIES SUCCESSFULLY COMPLETED AND \nFDA CLINICAL STUDY IN PROGRESS\n \n \nANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces unaudited results for the year ended 30 April 2018. \n \nOperational Highlights\n· FDA clinical study of 400 subjects set up and in progress with four leading US cancer centres, targeted for completion this year\n \n· Successful US and European ovarian cancer studies in 400 patients. Blood test delivered 95.1% accuracy in discriminating between benign and malignant pelvic masses significantly out-performing standard of care\n \n· Acquisition of the assets of Axela Inc. for £3.6 million. The principal asset, the Ziplex® platform allows multiplex gene expression analysis of cancer cells. This complements the ParsortixTM system and, in time, will be offered to customers as a full 'sample to answer' solution\n \n· Collaborative agreements signed with three leading, global healthcare companies QIAGEN, Philips and Abbott\n \n· Research equipment installed base increased to 200 Parsortix systems (2017: 145)\n \n· Total of 10 peer-reviewed publications (30 April 2017: 4) and 21 publicly available posters (30 April 2017: 13)\n \n \nFinancial Highlights\n \n· Loss for the year £7.5 million (2017: loss £6.4 million) reflecting planned investment\n \n· Revenue and grant income £0.7 million (2017: £0.5 million)\n \n· £15.0 million fundraising during the year (£14.4 million net of expenses)\n \n· Cash balance at 30 April 2018 of £7.6 million (30 April 2017: £5.5 million)\n \n· Post year end fundraising of £12.7 million (£12.0 million net of expenses)\n \nGarth Selvey, Non-Executive Chairman of ANGLE plc, comment...